Members of the Indiana University Health Special Pathogens Unit/Special Pathogens Program recently toured the Biocontainment Care Unit to learn more about our facilities and processes. From left to right: Dr. Doug Webb, Jennifer Burchett, Stephen Kitts, Mary Kay Foster, Derek Combs, and SPECTRE's Dr. Corri Levine.

New article published in Biomedicines by Dr. Olivier Escaffre, Dr. Peter Szaniszlo and Dr. Katalin Modis in collaboration with the UTMB Biorepository of Severe Emerging Infections (BSEI) and SPECTRE’s Dr. Susan McLellan and Dr. Corri Levine: Lung microvascular endothelial injury plays a critical role in the pathophysiology of COVID-19. The beneficial effects of Hydrogen Sulfide (H2S) in several pathological processes have provided a rationale for considering the therapeutic implications of H2S in COVID-19 therapy. This study was aimed to assess the effect of the slow-releasing of an H2S donor on the barrier function of a human lung microvascular epithelial cell (EC) monolayer in vitro, after challenging the cells with plasma samples from COVID-19 patients or inactivated SARS-CoV-2 virus.

SPECTRE Program Managers Kara Marshall and Corri Levine attend a roundtable meeting hosted by Sam Houston State University

Talk of the Town: President Trump’s Legal Troubles, the 2024 Presidential Race, The Tony Awards, Summer Entertainment, and More

SPECTRE is offering this webinar as a means to discuss practical considerations for health care institutions and partners when presented with a patient suspected of having a special pathogen. We will use example "paper patients "to walk through the steps necessary to provide appropriate care while maintaining public health and healthcare worker safety.

New article published in Open Forum of Infectious Diseases co-authored by SPECTRE’s Dr. Corri Levine: Appropriate representation is vital when conducting clinical trials and this is just as important during emerging infectious disease outbreaks. The Adaptive COVID-19 Treatment Trial (ACTT) was one of the first trials to test therapeutics against COVID-19, initiated early in the pandemic when very little was known about the disease and susceptible populations. This paper used ACTT as a model for selecting appropriate comparators when evaluating trial representation.